BioSpace News Archive

Kapoose Creek Bio, a Vancouver-based biotechnology company leveraging AI for drug discovery from nature, announced the identification and advancement of two lead compounds with exciting potential in neurology, spanning indications in neurodegeneration and mental health.

Catalyst Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has approved its supplemental New Drug Application (“sNDA”) increasing the indicated maximum daily dose of FIRDAPSE.

Akeso, Inc. announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary endpoint of progression-free survival.

Aura Biosciences, Inc. today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 12:30 p.m. ET.

Qualigen Therapeutics, Inc. announced today that on May 23, 2024, it received written notice (the “Delist Notice”) from The Nasdaq Stock Market (“Nasdaq”) indicating the Company’s continued non-compliance with the minimum bid price requirement, pursuant to Listing Rule 5550(b)(2).

Oncternal Therapeutics, Inc. today announced that enrollment has been completed and dosing initiated for the fifth dose cohort of its Phase 1/2 study of ONCT-534 for the treatment of patients with metastatic castration-resistant prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI).

Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the United States Food and Drug Administration (FDA) has selected nomlabofusp to participate in the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program.

Cytek Biosciences, Inc. today announced the company will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FL.

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, will host a commercial webinar on Tuesday, June 4, 2024, at 8:00 a.m. ET to discuss the market outlook for the Company’s three most advanced programs, ARIKAYCE.

Ongoing Phase 1/1b Clinical Trial Evaluating ONM-501, a Dual-activating STING Agonist, Alone and In Combination with Cemiplimab in Solid Tumors.